BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27416955)

  • 1. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
    Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
    Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model.
    Zalles M; Smith N; Ziegler J; Saunders D; Remerowski S; Thomas L; Gulej R; Mamedova N; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Wiley G; Brown C; Battiste J; Wren JD; Towner RA
    J Cell Mol Med; 2020 Jan; 24(2):1738-1749. PubMed ID: 31863639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.
    Ziegler J; Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Patel M; Wren JD; Lupu F; Battiste J; Towner RA
    Am J Nucl Med Mol Imaging; 2019; 9(1):93-109. PubMed ID: 30911439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model.
    Zalles M; Smith N; Saunders D; Saran T; Thomas L; Gulej R; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Battiste J; Towner RA
    Transl Oncol; 2020 Mar; 13(3):100737. PubMed ID: 32208341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ELTD1 as a multi-focal target for malignant gliomas: preclinical studies.
    Zalles M; Smith N; Saunders D; Guzman M; Lerner M; Fung KM; Babu A; Battiste J; Chung J; Hwang K; Jin J; Towner RA
    Neurooncol Adv; 2021; 3(1):vdab132. PubMed ID: 34704036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.
    Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Battiste J; Towner RA
    J Cell Mol Med; 2022 Jan; 26(2):570-582. PubMed ID: 34910361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELTD1, a potential new biomarker for gliomas.
    Towner RA; Jensen RL; Colman H; Vaillant B; Smith N; Casteel R; Saunders D; Gillespie DL; Silasi-Mansat R; Lupu F; Giles CB; Wren JD
    Neurosurgery; 2013 Jan; 72(1):77-90; discussion 91. PubMed ID: 23096411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
    Huang H; Georganaki M; Conze LL; Laviña B; van Hooren L; Vemuri K; van de Walle T; Ramachandran M; Zhang L; Pontén F; Bergqvist M; Smits A; Betsholtz C; Dejana E; Magnusson PU; He L; Lugano R; Dimberg A
    Neuro Oncol; 2022 Mar; 24(3):398-411. PubMed ID: 34347079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting.
    Hamans B; Navis AC; Wright A; Wesseling P; Heerschap A; Leenders W
    Neuro Oncol; 2013 Dec; 15(12):1615-24. PubMed ID: 24158109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.
    Seshadri M; Ciesielski MJ
    J Cereb Blood Flow Metab; 2009 Aug; 29(8):1373-82. PubMed ID: 19458603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasion as limitation to anti-angiogenic glioma therapy.
    Lamszus K; Kunkel P; Westphal M
    Acta Neurochir Suppl; 2003; 88():169-77. PubMed ID: 14531575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
    Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
    Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis.
    Anderson JC; Grammer JR; Wang W; Nabors LB; Henkin J; Stewart JE; Gladson CL
    Cancer Biol Ther; 2007 Mar; 6(3):454-62. PubMed ID: 17384534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
    Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
    J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1α signaling axis.
    Li J; Shen J; Wang Z; Xu H; Wang Q; Chai S; Fu P; Huang T; Anas O; Zhao H; Li J; Xiong N
    Sci Rep; 2019 Sep; 9(1):13904. PubMed ID: 31554859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.
    Towner RA; Smith N; Zalles M; Morris S; Toliver M; Saunders D; Lerner M; Kumar G; Axtell RC
    Mult Scler Relat Disord; 2021 Apr; 49():102786. PubMed ID: 33517175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.